share_log

Allarity Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-3i, LP(0%),3i Management LLC(0%), etc.

Allarity Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-3i, LP(0%),3i Management LLC(0%), etc.

Allarity Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-3i, LP(0%),3i Management LLC(0%)等
美股SEC公告 ·  11/14 10:28

Moomoo AI 已提取核心訊息

Allarity Therapeutics, Inc. has filed an Amendment No. 2 to the Schedule 13G with the U.S. Securities and Exchange Commission (SEC), indicating significant changes in ownership by reporting persons. The amendment, dated September 30, 2024, reflects the aftermath of a 1-for-30 reverse stock split of the company's common stock that occurred on September 9, 2024. The filing was made by three reporting persons: 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, all of whom have ceased to be the beneficial owners of more than five percent of Allarity Therapeutics' outstanding common stock. This amendment serves as an exit filing for each of the reporting persons, marking their departure from a significant ownership position in the company. The principal business address for all reporting persons is listed as 2 Wooster Street, 2nd Floor, New York, NY 10013. The filing emphasizes that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
Allarity Therapeutics, Inc. has filed an Amendment No. 2 to the Schedule 13G with the U.S. Securities and Exchange Commission (SEC), indicating significant changes in ownership by reporting persons. The amendment, dated September 30, 2024, reflects the aftermath of a 1-for-30 reverse stock split of the company's common stock that occurred on September 9, 2024. The filing was made by three reporting persons: 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, all of whom have ceased to be the beneficial owners of more than five percent of Allarity Therapeutics' outstanding common stock. This amendment serves as an exit filing for each of the reporting persons, marking their departure from a significant ownership position in the company. The principal business address for all reporting persons is listed as 2 Wooster Street, 2nd Floor, New York, NY 10013. The filing emphasizes that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
Allarity Therapeutics, Inc. 向美國證券交易委員會(SEC)提交了第2號修正的13G表,表示報告人擁有權發生了重大變化。該修正案日期爲2024年9月30日,反映了2024年9月9日公司普通股進行的1拆30的反向股票分割後的情況。此文件由三位報告人提交:3i, LP、3i Management LLC 和 Maier Joshua Tarlow,他們均已不再是Allarity Therapeutics已發行普通股超過五個百分點的受益所有人。該修正案作爲每位報告人的退出文件,標誌着他們退出了公司顯著的持股地位。所有報告人的主要商業地址列爲紐約州紐約市沃斯特街2號2樓,郵政編碼10013。該文件強調,這些股份並不是爲了改變或影響發行人的控制權而獲得的。
Allarity Therapeutics, Inc. 向美國證券交易委員會(SEC)提交了第2號修正的13G表,表示報告人擁有權發生了重大變化。該修正案日期爲2024年9月30日,反映了2024年9月9日公司普通股進行的1拆30的反向股票分割後的情況。此文件由三位報告人提交:3i, LP、3i Management LLC 和 Maier Joshua Tarlow,他們均已不再是Allarity Therapeutics已發行普通股超過五個百分點的受益所有人。該修正案作爲每位報告人的退出文件,標誌着他們退出了公司顯著的持股地位。所有報告人的主要商業地址列爲紐約州紐約市沃斯特街2號2樓,郵政編碼10013。該文件強調,這些股份並不是爲了改變或影響發行人的控制權而獲得的。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息